California: MedGenome presented data on its proprietary cancer immunotherapy platform, OncoPept that predicts and prioritizes T-cell neo-epitopes in human and mouse cancers at the Molecular Medicine Tri- Conference 2016, which took place on March 6 – 11, 2016 at San Francisco, CA.
Many pre-clinical and clinical studies have documented the power of T-cell neo epitopes in shaping the immune response to eliminate cancer – the basis for the development of cancer vaccines. MedGenome’s OncoPept platform combines exome and RNA-sequencing data and prioritizes the neo-epitopes further with advanced analytics. The platform combines deep sequencing to identify rare variants present in less than 5% of tumor cells to increase the repertoire of mutations that may be targeted by T-cells. The number of mutations is further reduced using multiple prioritization steps to a small list that can be tested as cancer vaccines. In addition, OncoPept seeks to address the challenge faced by the oncology community at large, to discover tumor-intrinsic and extrinsic factors that will increase the patient response to the checkpoint inhibitor drugs significantly over what is achieved to date.